Houston, TX., July 11, 2018 (GLOBE NEWSWIRE) — AngioSoma (OTC: SOAN) today launched a new corporate logo and website, marking the most dramatic change in its visual identity since 2016. Taking a more modern approach to developing a more differentiated corporate mark, the brighter blue color and a complementary color pallet of orange, grey, and dark blue better reflect the progressive corporate brand as it heads toward new product launches and market opportunities in 2018.
“Our new visual expression of our business better communicates where AngioSoma is headed in the coming years,” said AngioSoma president and chief executive officer, Alex Blankenship. “We’ve also made changes to other visual elements of our product brands and subsidiaries to better reflect position in the market and emphasize our forward-thinking mindset. We anticipate more updates to our external communications with the clear objective to achieve strong growth, drive investor value and focus on innovation.”
Designed in partnership with an award-winning Houston firm, the new visual identity presents AngioSoma as contemporary and evolving, reflecting the direction of its brand portfolio, and accentuates its commitment to its exciting product roadmap. The logo also utilizes “AngioSoma” as the mark itself as a way to distinguish the corporate identity from its other corporate and direct-to-consumer brands.
Pleasee visit https://angiosoma.com/marketing to download AngioSoma’s new logo.
ABOUT ANGIOSOMA, INC.
AngioSoma, Inc. (https:// angiosoma.com), a Nevada corporation based in Houston, Texas, is dedicated to improving the mental and physical wellbeing of men and women. To accomplish that purpose, we are launching a line of supplements under our SomaceuticalsTM common identity. Our supplements cover three industry segments: nutraceuticals, cosmeceuticals, and pharmaceuticals.
NOTICE REGARDING FORWARD LOOKING STATEMENTS
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements.
Contacts AngioSoma, Inc. Alex Blankenship investors@AngioSoma.com